/
For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients.
The business is unprofitable at the operating level (-40.45% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 33.8% YoY with margins expanding 26.9pp.
Negative free cash flow of -$320M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$1.06B
▲ +33.8% YoY
Net Income (TTM)
-$327M
▲ +16.0% YoY
Op. Margin
-33.29%
▲ +26.9pp YoY
ROIC
-22.49%
▲ +6.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$971M
▲ +41.4% YoY
Op. Cash Flow (TTM)
-$911M
▲ +46.4% YoY
Net Debt
-$1.66B
Net Cash Position
Cash & Equiv.
$1.92B
5Y CAGR: +5.3%
Continue Research